Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Chemotherapy-Induced
Peripheral Neuropathy (CIPN) Market Outlook
Thelansis’s “Chemotherapy-Induced
Peripheral Neuropathy (CIPN) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2026 To 2036” covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Chemotherapy-Induced Peripheral Neuropathy (CIPN) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Chemotherapy-Induced
Peripheral Neuropathy (CIPN) Overview
Chemotherapy-induced peripheral
neuropathy (CIPN) is a prevalent and often dose-limiting toxicity resulting
from neurotoxic antineoplastic agents, most notably taxanes, platinum
compounds, and vinca alkaloids. Pathogenesis involves multifaceted damage to
the peripheral nervous system, including axonal degeneration, mitochondrial
dysfunction, and direct injury to the dorsal root ganglia, which are vulnerable
due to high metabolic activity and a permeable blood-nerve barrier. Clinically,
CIPN manifests as a symmetric sensory impairment in a glove-and-stocking
distribution, characterized by numbness, paresthesia, and burning pain, and may
involve a coasting effect where symptoms progress after treatment cessation.
Risk is exacerbated by cumulative drug exposure, advanced age, and pre-existing
diabetes. As there are no approved preventive agents, symptomatic management
relies on the SNRI duloxetine as the frontline evidence-based intervention,
while severe symptoms necessitate dose delays or permanent treatment discontinuation.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment